Gilead Sciences has long been in need of a catalyst to move its business, and a lot of investors and analysts alike have considered this company dead money until something happens.
The top analyst upgrades, downgrades and initiations seen on Monday include AIG, Boeing, GameStop, Gilead Sciences, Starbucks, CIGNA, Ciena and Ferrari.
The February 28 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
The top analyst upgrades, downgrades and initiations seen on Thursday include American Express, Amgen, Encana, Gilead Science and Tesla.
The February 15 short interest data have been compared with the previous report, and short interest increased in all the selected biotech stocks.
These five top companies havehit some economic potholes but are primed for a comeback. They all are well known, make a variety of consumer and commercial products and will be around in…
After Gilead Sciences reported fourth-quarter earnings on Tuesday, the stock hit a new multiyear low and analysts took the opportunity to slash their price targets.
Chris Lange As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears have to say about this rally.
Vista Outdoor, Gilead Sciences, Fitbit, and Fossil posted new 52-week lows on Thursday.
Gilead Sciences, Gale Biopharma, Teva, and Fitbit post new 52-week lows Wednesday.
24/7 Wall St. has included some highlights from the Gilead Sciences earnings report, as well as what analysts are saying afterward.
Chris Lange Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made splash, while one giant company posted a massive loss.
The op analyst upgrades, downgrades and initiations seen on Wednesday include Broadcom, Cheniere Energy, Gilead Sciences, Microchip Technology, Twitter, Lennar and Bankrate.
Gilead Sciences Inc. (NASDAQ: GILD) reported its fourth-quarter earnings after the markets closed on Tuesday. The company posted $2.70 in earnings per share (EPS) and $7.3 billion in revenue, compared with the…
Chris Lange Gilead Sciences is set to report its fourth-quarter financial results after the markets close on Tuesday.
Chris Lange 
